Research location
Braintree
Massachusetts, United States
Advertisement
Research activity in Braintree
Massachusetts, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 20 trials and 20 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Braintree
20 linked trials · page 1 of 1A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinNCT07662135 · 2026-07-06 · 1 site observation
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
[18F]PI-2620 Phase 3 Histopathological StudyNCT05641688 · 2022-12-01 · 1 site observation
RECRUITING
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509 · 2024-11-21 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886 · 2024-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409 · 2022-09-06 · 1 site observation
COMPLETED
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT04947553 · 2021-06-17 · 1 site observation
COMPLETED
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)NCT04867616 · 2021-06-09 · 1 site observation
COMPLETED
A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseNCT04619420 · 2021-01-06 · 1 site observation
TERMINATED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT03393520 · 2017-10-13 · 1 site observation
COMPLETED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02446132 · 2015-11-13 · 1 site observation
TERMINATED
A Safety, Efficacy and Tolerability Study of SEP-225289NCT00584974 · 2007-12-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderNCT00467402 · 2007-04-01 · 1 site observation
COMPLETED
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive DisordersNCT00326105 · 2006-04-01 · 1 site observation
COMPLETED
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive DisordersNCT00326144 · 2006-04-01 · 1 site observation
COMPLETED
Sexual Functioning Study With AntidepressantsNCT00316160 · 2004-09-01 · 1 site observation
COMPLETED
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive DisorderNCT00368030 · 2004-01-01 · 1 site observation
COMPLETED
Depression Study In Elderly PatientsNCT00067444 · 2003-06-01 · 1 site observation
COMPLETED
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskNCT00056407 · 2003-03-01 · 1 site observation
COMPLETED
Effects Of Antidepressants On Sexual Functioning In AdultsNCT00051272 · 2003-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.